BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10192497)

  • 21. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
    Pinke DE; Kalloger SE; Francetic T; Huntsman DG; Lee JM
    Gynecol Oncol; 2008 Mar; 108(3):561-8. PubMed ID: 18164751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
    Sabatier R; Calderon B; Lambaudie E; Chereau E; Provansal M; Cappiello MA; Viens P; Rousseau F
    Int J Gynecol Cancer; 2015 Jun; 25(5):815-22. PubMed ID: 25768081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database.
    McNally L; Teng NN; Kapp DS; Karam A
    Int J Gynecol Cancer; 2015 May; 25(4):607-15. PubMed ID: 25756404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
    Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
    J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
    Nasioudis D; Chapman-Davis E; Witkin SS; Holcomb K
    Gynecol Oncol; 2017 Feb; 144(2):414-419. PubMed ID: 27908528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
    Mizuno M; Kikkawa F; Shibata K; Kajiyama H; Ino K; Kawai M; Nagasaka T; Nomura S
    J Surg Oncol; 2006 Aug; 94(2):138-43. PubMed ID: 16847906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.
    Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
    Cancer Imaging; 2016 Feb; 16():3. PubMed ID: 26873307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
    Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer.
    Hefler LA; Grimm C; Ackermann S; Malur S; Radjabi-Rahat AR; Leodolter S; Beckmann MW; Zeillinger R; Koelbl H; Tempfer CB
    Cancer Res; 2003 Jun; 63(12):3066-8. PubMed ID: 12810629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
    Lydiksen L; Jensen-Fangel S; Blaakaer J
    Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.